Is Ketamine a Psychedelic? The Classification, and Why It Matters

The question comes up constantly, and it deserves a straight answer rather than a definitional shrug: no, ketamine is not a classic serotonergic psychedelic; it is a dissociative anaesthetic that is often described as an atypical psychedelic or psychedelic-adjacent, because some of the subjective effects overlap and "psychedelic" is not a universally fixed pharmacological category. Both halves of that answer are true, and the interesting part is what follows from each.

What ketamine actually is

Ketamine has been a hospital anaesthetic since the 1970s and sits on the WHO list of essential medicines. The form used in most depression research is racemic ketamine, a 50:50 mix of two mirror-image molecules, S-ketamine (esketamine) and R-ketamine. Esketamine is one of those two molecules, isolated and developed into an approved nasal-spray medicine, Spravato, authorised EU-wide since December 2019. Spravato now has two EU-authorised indications: treatment-resistant major depressive disorder, taken with an SSRI or SNRI, and acute short-term reduction of depressive symptoms in a moderate-to-severe major depressive episode judged to constitute a psychiatric emergency. It has not been shown to prevent suicide or directly reduce suicidal ideation or behaviour. Racemic ketamine, by contrast, has never been approved as an antidepressant anywhere in Europe, so its use for depression is off-label: legal, but outside the licence.

Its mechanism is where the classification argument starts. Ketamine is an NMDA-receptor antagonist; its rapid antidepressant effects are thought to involve downstream glutamate release, AMPA-receptor signalling, neurotrophic pathways and changes in synaptic function, but the complete mechanism remains incompletely understood, and that rapid action is why relief can arrive within hours rather than the weeks conventional antidepressants take. Our ketamine evidence review covers what that effect looks like in trials.

What "psychedelic" usually means

Used strictly, "psychedelic" means the classic serotonergic compounds. Psilocybin is the standard example: a naturally occurring compound converted in the body to psilocin, which acts mainly at the serotonin 2A receptor, given as a purified or synthetic compound in one or two supervised sessions with preparation and integration around them (psilocybin evidence review). LSD works on the same receptor family.

MDMA is already an exception to the strict definition. It is not a classic psychedelic but an entactogen: it increases release of serotonin, dopamine and noradrenaline, tends to reduce fear responses and increase feelings of trust and openness, and in research is given in two or three supervised sessions inside a longer psychotherapy course (MDMA evidence review).

Ketamine is a third category again: a dissociative. Where the classic psychedelics tend to produce perceptual and emotional intensification, dissociation is more often described as detachment: a dreamlike sense of distance from body and surroundings. It is expected during dosing, it is one of the effects clinics monitor for, and it resolves as the drug clears.

Why the label matters in practice

If the answer were purely academic, it would not be worth 1,000 words. It matters for three reasons.

Legality. Because racemic ketamine is a licensed anaesthetic, doctors can generally prescribe it off-label for depression (though off-label prescribing rules, professional standards, governance and reimbursement vary country by country), and that is why a private clinic market exists at all. Psilocybin and MDMA are controlled substances with no general medical route: outside clinical trials, lawful psilocybin treatment exists through narrow exceptional or compassionate pathways in three countries and lawful MDMA therapy in one, and none of those pathways is equivalent to routine, self-referral access. That legal starting point is a major reason ketamine dominates the European treatment landscape, though not the only one: evidence, clinical infrastructure, cost and clinician familiarity all push the same way. Our Europe-wide availability map sets out who can access what, and is ketamine therapy legal? covers the ketamine-specific rules country by country.

Evidence. Grouping the compounds together invites the assumption that they share an evidence base. They do not. Controlled evidence for ketamine's rapid antidepressant effect began with a small trial in 2000 and was replicated in treatment-resistant depression in the landmark 2006 trial; the 2021 Cochrane review found a rapid short-term effect after a single dose that generally attenuated over days and was no longer evident by about two weeks, with varying certainty and mostly short trials, repeated and maintenance regimens are a separate, still-unsettled question. Esketamine passed a full regulatory programme that enrolled 1,833 adults (1,601 exposed to esketamine), though not every pivotal study was statistically positive: TRANSFORM-2 met its primary endpoint, while the 84-mg arm of TRANSFORM-1 and the older-adult TRANSFORM-3 did not, and SUSTAIN-1 was a randomised-withdrawal maintenance study in patients who had already responded or remitted. By February 2026 both pivotal COMP360 psilocybin Phase 3 trials had reported positive sponsor-announced topline results; full peer-reviewed reporting and regulatory review remain pending, and psilocybin has no EU marketing authorisation for depression. Ketamine-assisted psychotherapy (the format most often marketed as "psychedelic therapy") is promising but under-evidenced, with no large trial cleanly separating the drug effect from the psychotherapy. The comparison between the two ketamine products is in our Spravato vs ketamine guide.

Risk. "Psychedelic" is a description of experience, not a safety category, and ketamine's risks are its own. Acute effects include dissociation, sedation, nausea, dizziness, cognitive and motor impairment, a transient rise in blood pressure and, rarely, respiratory depression. Bladder and urinary-tract damage (ketamine uropathy) and dependence are chiefly risks of repeated or chronic exposure, and depend on dose, route and frequency, which is why repeated treatment belongs in a monitored clinical setting rather than at home. Some psychiatric cautions do overlap with the classic psychedelics: current product information advises caution in psychosis and in people with a history of mania or bipolar disorder, alongside assessment of misuse risk.

So what should you call it?

In a clinic, "dissociative" is the accurate word and the one a psychiatrist is likely to use. In the wider field, ketamine is treated as psychedelic-adjacent, and that is not sloppiness: the delivery models genuinely overlap. Screening for psychiatric and cardiovascular history, supervised dosing with monitoring, a recovery period and structured follow-up describe a ketamine session and a psilocybin session about equally well. The overlap is not identity, though: psychotherapy, preparation and integration are not part of the licensed Spravato protocol and are not universal in IV-ketamine care, and the evidence that adding psychotherapy improves outcomes remains limited and heterogeneous. Aftercare rules also differ by product, after Spravato, do not drive, operate machinery or undertake hazardous activities until the next day following a restful sleep; after other treatments, follow the clinic's discharge instructions, including not driving yourself home.

The useful conclusion is to stop asking which box the molecule belongs in and start asking what is actually on offer where you live. If you want the practical answer for your country, our eligibility check runs in your browser and stores nothing, and the directory lists the ketamine and ketamine-assisted psychotherapy clinics we have verified.

Frequently asked questions

Is ketamine a psychedelic drug?

Not in the strict pharmacological sense. Ketamine is a dissociative anaesthetic acting on NMDA glutamate receptors, whereas classic psychedelics such as psilocybin and LSD act mainly at the serotonin 2A receptor. In everyday usage (clinics, conferences, directories), it is grouped with psychedelics, often as an "atypical psychedelic", because the subjective effects overlap and the treatment models overlap substantially.

Does ketamine cause hallucinations?

The typical experience is dissociation (a detached, dreamlike feeling) along with mild perceptual changes, rather than the vivid visual imagery associated with a full psilocybin or LSD dose. These effects are expected during dosing, are part of what clinical staff monitor, and settle as the drug is metabolised.

Is ketamine the same thing as Spravato?

Related, not the same. Spravato is esketamine, one of the two mirror-image molecules that make up racemic ketamine, developed into an approved nasal spray with its own EU authorisation and its own trial programme. Racemic ketamine is the older generic anaesthetic, used off-label. They differ in approval, setting, monitoring rules and cost; see our side-by-side comparison.

If ketamine is not a psychedelic, why is it in a psychedelic directory?

Because patients are looking for the same thing: a supervised, screened, medically delivered session with a compound that alters consciousness, followed by structured aftercare. Ketamine is the version of that model which is legally available in most of Europe today, so leaving it out would be tidy taxonomy and useless information.

Is ketamine safer than psilocybin because it is a medicine?

Being licensed as an anaesthetic means it has a known, regulated safety profile in that setting, not that it is risk-free as a repeated depression treatment. Common transient effects include dissociation, nausea, and a short-lived rise in blood pressure and heart rate; repeated use adds bladder-damage and dependence risks that require monitoring. Every route needs proper screening; see our clinic-choice guide.

Sources

1. EMA: Spravato (esketamine) EPAR
2. Spravato — EU Summary of Product Characteristics (sections 4.1, 4.4, 5.1)
3. Berman et al. (2000), Biological Psychiatry — first controlled trial of IV ketamine in depression
4. Zarate et al. (2006), Archives of General Psychiatry — single-infusion ketamine in treatment-resistant depression
5. Dean et al. (2021), Cochrane Database of Systematic Reviews — ketamine and other glutamate receptor modulators for depression in adults
6. Marguilho et al. (2023) — ketamine as an atypical psychedelic: a review
7. British Association of Urological Surgeons consensus on ketamine uropathy, BJU International (2024)
8. Compass Pathways (17 February 2026) — second COMP360 psilocybin Phase 3 trial meets primary endpoint (sponsor announcement)
9. Swiss FOPH — exceptional licences for banned narcotics
10. CIMH Mannheim — first German compassionate-use programme for psilocybin
11. Czech NUDZ — official statement on the availability of psilocybin treatment
12. Blossom — compound overviews
13. Psychedelic Alpha — worldwide psychedelic laws tracker

---

This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations change; discuss your options with a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.

Medically reviewed by Dr. Christopher Gauci, MD MRCS(Ed) EDAIC, on 16 August 2026.